FOLD — Amicus Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
Amicus Therapeutics Inc (FOLD) is a biotechnology company listed on NASDAQ. It is led by Bradley L. Campbell M.B.A., based in 47 Hulfish Street, Princeton, NJ, United States, 08542, with about 499 employees. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Latest reported FOLD revenue for 2025-09-30 was $169.1M. Net income was -$28.8M. Revenue was up 9.3% from 2025-06-30 to 2025-09-30. FOLD currently screens at market cap $1.80B.
Use this FOLD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FOLD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FOLD SEC filings page. Lician reads the product cache first so this HTML stays unique to Amicus Therapeutics Inc even when a live quote feed is slow.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
FOLD Key Statistics
Market Cap
$1.80B
EPS
-$0.18
Revenue
$528.29M
Net Income
-$56.11M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+32.3%
Profit Margin
-10.6%
Employees
499
FOLD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $528.29M | $399.36M | $329.23M | $305.51M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$56.11M | -$151.58M | -$236.57M | -$250.46M |
| EPS (Diluted) | -$0.18 | -$0.51 | -$0.82 | -$0.92 |
Total Assets
$785.03M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$213.75M
Operating Cash Flow
-$33.89M
Free Cash Flow
$0.00
Amicus Therapeutics Inc Company Information
- CEO, President & Director
- Bradley L. Campbell M.B.A.
- Headquarters
- 47 Hulfish Street, Princeton, NJ, United States, 08542
- Website
- amicusrx.com
- Phone
- 609 662 2000
- IPO / Founded
- 2007-05-31
- Sector
- Healthcare
- Industry
- Biotechnology